Fortrea Holdings Inc. (FTRE)
Fortrea Holdings: The Turnaround Is Showing Up In Earnings Before Revenue
Fortrea Holdings Inc. is rated Buy at ~$18.86, driven by an earnings turnaround from aggressive cost reductions, not revenue growth. Adjusted EBITDA rose ~24% in H1 despite a ~3.4% revenue decline, as direct costs and SG&A fell faster than sales. Net new business awards increased ~19% YoY, with a trailing-12-month book-to-bill ratio of 1.12x, but revenue conversion remains uncertain.
Fortrea Holdings Inc. (FTRE) Upgraded to Strong Buy: Here's What You Should Know
Fortrea Holdings Inc. (FTRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
FTRE vs. ARGX: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Fortrea Holdings Inc. (FTRE) Is Attractively Priced Despite Fast-paced Momentum
Fortrea Holdings Inc. (FTRE) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Fortrea Q2 Earnings Call Highlights
Fortrea NASDAQ: FTRE reported second-quarter 2026 revenue of $678.2 million and adjusted EBITDA of $58.7 million, while raising its full-year revenue and adjusted EBITDA outlook. Management said results reflected stronger clinical pharmacology performance, cost-savings initiatives and improving commercial activity, particularly among biotechnology clients.
Fortrea Holdings Inc. (FTRE) Surpasses Q2 Earnings and Revenue Estimates
Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.19 per share a year ago.
FTRE or ARGX: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
Fortrea Holdings Inc. (FTRE) Beats Q1 Earnings Estimates
Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.02 per share a year ago.
Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth
Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fortrea Holdings Inc. (FTRE) Q4 Earnings and Revenues Lag Estimates
Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.18 per share a year ago.
FTRE vs. PRTA: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and Prothena (PRTA). But which of these two stocks is more attractive to value investors?
FTRE or ACAD: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Fortrea Holdings Inc. (FTRE) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attractive to value investors?
